Reprint

Cardiovascular Disease

From Molecular Mechanisms to Clinical Therapies

Edited by
April 2021
469 pages
  • ISBN978-3-0365-0993-8 (Hardback)
  • ISBN978-3-0365-0992-1 (PDF)

This book is a reprint of the Special Issue Cardiovascular Disease: From Molecular Mechanisms to Clinical Therapies that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

According to the most updated epidemiological studies, cardiovascular disease remains a leading cause of death; in fact, despite substantial advances in the care of patients, the incidence of cardiovascular disorders continues to increase. Therefore, the search for novel mechanisms and therapeutics is desperately needed, and translational studies represent the best strategy to uncover novel therapeutic targets, reduce mortality, and improve the quality of life. This book gathers original articles and systematic reviews that have both a strong basic research background and clear translational potential. All the studies have been peer reviewed by at least two experts in the field. These contributions provide an updated systematic overview that examines, in detail, the mechanisms of the main cardiovascular and metabolic disorders, including ischemic and non-ischemic heart failure, hypertension, thromboembolism, atherosclerosis, stroke, diabetes mellitus, dyslipidemia, metabolic syndrome, valvulopathies, peripheral artery disease. In the final chapter, the functional role of the endothelium in the systemic manifestations of COVID-19 is described.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
sugar; atherosclerosis risk factors; lipoprotein fractions; TG-rich lipoproteins; clinical studies; LDL; lipid and lipoprotein metabolism; nutrition/carbohydrates; coronary artery disease; human; inflammation; lymphangiogenesis; perivascular adipose tissue; human performance; aerobic training; genetic predisposition; lipid metabolism; glucose tolerance; VO2max; mitochondria activity; cholesterol levels; left ventricular hypertrophy; heart failure with preserved ejection fraction; population study; stroke volume; heart rate; echocardiography; coronary artery disease; diabetes mellitus; atherosclerosis; coronary angiography; stroke; amphetamines; cocaine; cannabis; morphine; heroin; synthetic cannabinoids; anabolic androgenic steroids; peripheral artery disease (PAD); metabolomics; claudication; critical limb ischemia (CLI); neutrophil extracellular traps; citrullinated histone H3; cardiac arrest; neurologic function; cerebral blood volume; hemodynamics; near-infrared spectroscopy; optical imaging; rehabilitation; stroke; GRP78/BiP; endoplasmic reticulum stress; atherosclerosis; carotid intima–media thickness; obesity; type 2 diabetes; metabolic syndrome; cardiovascular risk; fenofibrate/niacin treatment; acute heart failure; advanced heart failure; short-term hemodynamic therapy; regulatory clinical trials; clinical development; levosimendan; mediterranean diet; supply chain of food; metabolic syndrome; food retail; cardiovascular risk; IL-1β; Canakinumab; arterial thrombosis; tissue factor; neutrophil extracellular traps; Neopterin; inflammation; heart failure; adverse outcome; statin; pharmacogenomics; muscle toxicity; mitochondria; prenylation; immune system; cardiac arrest; resistin; post-cardiac-arrest shock; hypertension; renin-angiotensin-aldosterone system; MasR; angiotensin-(1-7); ambulatory blood pressure monitoring; cardiovascular disease; children; chronic kidney disease; dimethylamine; gut microbiota; hypertension; trimethylamine; trimethylamine N-oxide; antioxidants; calcium sensitizer; heart failure; mitochondria function; peroxidation; cardiovascular diseases; circadian rhythm; clock genes; myocardial infarction; polymorphisms; hypertension; prehypertension; exercise; diet; adhesion molecule; sICAM; soluble intercellular adhesion molecule; inflammatory markers; intervention; Alzheimer; ataxia; autoimmune disease; cancer; cardiovascular disease; diabetes; GWAS; IP3 Receptors; ITPRs; mutations; natriuretic peptides; mitral valve regurgitation; valve repair; valve replacement; risk prediction; ACE2, acute kidney injury; blood pressure; catepsin; coronavirus; COVID; cytokine storm; endothelium; heparin; Kawasaki disease; hypertrophic cardiomyopathy; cardiopulmonary exercise test; genetic testing; angiopoietins; heart failure; VEGFs; sPLA2; IHF; NIHF; natriuretic peptides; brain; cognitive decline; dementia; cardiovascular diseases; stroke; hypertension; TNF-α; TNFR1; TNFR2; heart; cardiovascular disease; inflammation; cardiac fibrosis